Journals / Glokom Katarakt / 2018 / Cilt: 13 - Sayı: 1

Molybdenum Cofactor Defi ciency and Lens Dislocation: A Case Report

Molibden Kofaktör Eksikliği ve Lens Dislokasyonu: Olgu Sunumu

Pages
38–41
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Since progression of neurodegenerative disorders may be delayed and refractory seizures may be ceased with appropriate diet and treatment, early diagnosis is extremely important.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We wanted to emphasize the importance of ocular examination in an uncommon and lethal metabolic disease, Molybdenum Cofactor Defi ciency, which appears with refractory seizures during early neonatal period.
📊
Key Findings & Data:This exteremely rare case is important in recognition and discussion of a less known disease Molybdenum Cofactor defi ciency characterized by lens dislocation and refractory seizures in pediatric patients.
💡
Conclusion & Impact:Since progression of neurodegenerative disorders may be delayed and refractory seizures may be ceased with appropriate diet and treatment, early diagnosis is extremely important.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We wanted to emphasize the importance of ocular examination in an uncommon and lethal metabolic disease, Molybdenum Cofactor Defi ciency, which appears with refractory seizures during early neonatal period. This exteremely rare case is important in recognition and discussion of a less known disease Molybdenum Cofactor defi ciency characterized by lens dislocation and refractory seizures in pediatric patients. Since progression of neurodegenerative disorders may be delayed and refractory seizures may be ceased with appropriate diet and treatment, early diagnosis is extremely important.

Özet

Erken çocukluk döneminde tedaviye dirençli nöbetlerle kendini gösteren, nadir ve ölümcül bir metabolik hastalık olan Molibden Kofak- tör Eksikliği tanısında göz muayenesinin önemini vurgulamak istedik. Bu çok nadir görülen vaka, lens dislokasyonu ile beraber tedaviye dirençli nöbeti olan çocuklarda erken tanı ve tedaviye olanak sağlaması için, az bilinen bir hastalık olan Molibden Kofaktör Eksikliği’nin hatırlatılması ve tartışılması açısından önem arz etmektedir. Bu hastalarda, uygun diyetle ve tedavi ile en azından nörodejeneratif bozuk- lukların ilerleyişi durdurulabileceğinden ve dirençli nöbetler kesilebileceğinden erken tanı oldukça önemlidir.

🔖

Cite This Article

DUMAN, F., GENÇPINAR, P. (2018). Molybdenum Cofactor Defi ciency and Lens Dislocation: A Case Report. Glokom Katarakt, Cilt: 13 - Sayı: 1, 38–41. https://ajindex.com/articles/164991

References (14)

  1. Duran M, Beemer FA, van de Heiden C, ve ark. Combined defi - ciency of xanthine oxidase and sulphite oxidase: a defect of mol- ybdenum metabolism or transport? J Inherit Metab Dis.1978; 1: 175-8.
  2. Johnson JL, Waud WR, Rajagopalan KV, ve ark. Inborn errors of molybdenum metabolism: combined defi ciencies of sulfi te oxida- se and xanthine dehydrogenase in a patient lacking the molybde- num cofactor. Proc Nat Acad Sci.1980; 77: 3715-9. Ichida K. Hereditary xanthinuria and molybdenum cofactor defi - ciency. Nippon Rinsho.2003; 61: 377-82.
  3. Havemeyer A, Lang J, Clement B. The fourth mammalian molyb- denum enzyme mARC: Current state of research. Drug Metab Rev 2011; 43: 524-39.
  4. Schwartz G, Mendel RR, Ribbe MW. Molybdenum cofactors, en- zymes and pathways. Nature.2009; 460: 839-47.
  5. Lueder GT, Steiner RP. Ophthalmic abnormalities in molybdenum cofactor defi ciency and isolated sulfi te oxidase defi ciency. J Pedi- atr Ophthalmol Strabismus.1995; 32: 334-7.
  6. Reiss J, Bonin M, Schwegler H, ve ark. The pathogenesis of mol- ybdenum cofactor defi ciency, its delay by maternal clearance, and its expression pattern in microarray analysis. Mol Genet Me- tab.2005; 85: 12-20.
  7. Vijayakumar K, Gunny R, Grunewald S, ve ark. Clinical neuroi- maging features and outcome in molybdenum cofactor defi ciency. Pediatr Neurol.2011; 45: 246-52.
  8. Bayram E, Topcu Y, Karakaya P, ve ark. Molybdenum cofactor defi ciency: review of 12 cases (MoCD and review). Eur J Paediatr Neurol.2013; 17: 1-6.
  9. Bindu PS, Christopher R, Mahadevan A, ve ark. Clinical and ima- ging observations in isolated sülfi te oxidase defi ciency. J Child Neurol.2011; 26: 1036-40. Panayiotopoulos CP. Neonatal seizures, neonatal syndromes. In: The Epilepsies: Seizures, Syndromes and Management. Oxfords- hire (UK): Bladon Medical Publishing; 2005. Available at: http// www.ncbi.nlm.nih.gov/books/NBK2599/. Accessed May 10, 2016.
  10. Hitzert MM, Bos AF, Bergman KA, ve ark. Favorable outcome in a newborn with molybdenum cofactor type A defi ciency treated with cPMP. Pediatrics.2012; 130: 1005-10.
  11. Al-Obaidalla MA, Mbekeani JN, Dogar MA, ve ark. Neonatal molybdenum cofactor defi ciency and ectopia lentis in a Saudi Ara- bian patient. Int J Ped and Adolesc Med. 2014; 1: 35-9.
  12. Nagappa M, Bindu PS, Taly AB, ve ark. Child Neurology: Molyb- denum cofactor defi ciency. Neurology.2015; 85: 175-8.
  13. Gray RGF, Green A, Basu SN, ve ark. Antenatal diagnosis of mol- ybdenum cofactor defi ciency. Am J Obstet Gynecol.1990; 163: 1203-4.
  14. Reiss J, Christen